This study seeks to evaluate the clinical utility of the Precision Medicine Molecular Tumor Board, and to track patient outcomes.
Study Type
OBSERVATIONAL
Enrollment
10,000
PMMTB is a clinical intervention, NOT a research intervention. The research component of this study is to observe the outcomes of the PMMTB.
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, United States
RECRUITINGFrequency of acceptance of molecular tumor board recommendations
How often the molecular tumor board's recommendations are accepted
Time frame: Up to 5 years
Benefit from PMMTB recommended treatment
Whether patients benefit from PMMTB recommended treatment
Time frame: Up to 5 years
Correlation of mutations with protein overexpression
Correlate mutations identified in tumor tissue with protein overexpression
Time frame: Up to 5 years
Correlations of mutations with circulating tumor DNA
Correlate mutations identified in tumor tissue with circulating tumor DNA
Time frame: Up to 5 years
Correlations of mutations with spheroid culture investigations
Correlate mutations identified in tumor tissue with spheroid culture investigations
Time frame: Up to 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.